28 Oct, 2016

Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect”

alzheon2019-09-23T12:10:50-04:00October 28th, 2016|

Read More

25 Oct, 2016

‘Gene-dose’ effect for Alzheon’s ALZ-801, a drug targeting Alzheimer’s disease

alzheon2019-09-23T12:10:52-04:00October 25th, 2016|Tags: thepharmaletter|

Read More

24 Oct, 2016

Alzheon Publishes New Analyses from Phase 3 Studies Showing Clinical Benefit of Tramiprosate in Alzheimer’s Patients Who Are Carriers of APOE4, the Major Genetic Risk Factor in up to 65 Percent of Alzheimer’s Patients

alzheon2019-09-23T12:10:52-04:00October 24th, 2016|

Read More

7 Oct, 2016

A Little-Known Drug Company Could Have The Answer For Some Alzheimer’s Patients

alzheon2019-09-23T12:10:52-04:00October 7th, 2016|Tags: Forbes.com|

Read More

4 Oct, 2016

Alzheon to Present at Upcoming Asian Healthcare and Scientific Conferences

alzheon2024-07-10T14:06:37-04:00October 4th, 2016|

Read More

21 Sep, 2016

Alzheon to Present at Upcoming Investor Conferences

alzheon2024-07-10T14:07:05-04:00September 21st, 2016|

Read More

7 Sep, 2016

Alzheon to Present at Upcoming Industry Conferences

alzheon2024-07-10T14:06:49-04:00September 7th, 2016|

Read More

25 Jul, 2016

Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII

alzheon2024-07-10T14:05:18-04:00July 25th, 2016|Tags: fiercebiotech.com|

Read More

25 Jul, 2016

Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer’s Patients with APOE4/4 Homozygous Genotype

alzheon2019-09-23T12:10:52-04:00July 25th, 2016|

Read More

24 Jul, 2016

Clinically Meaningful Cognitive and Functional Improvements with Tramiprosate In Alzheimer’s Disease (AD) Patients with APOE4/4 Genotype: Subgroup Analyses from Two Phase 3 Studies

alzheon2019-09-23T12:10:52-04:00July 24th, 2016|

Read More